Allograft Injury

Among pediatric patients who received a kidney-only transplantation, high tacrolimus intrapatient variability significantly correlated with de novo donor-specific antibody formation.

In this video, Philippe Gauthier, MD, a transplant nephrologist and senior medical director of organ health at Natera, discusses a two-threshold algorithm that uses donor-derived cell-free DNA and quantity to detect transplant rejection.

Donor-derived cell-free DNA was determined to be a leading indicator of allograft injury, eGFR decline, formation of de novo donor-specific antibodies and subclinical rejection, according to published data.

Restoring pre-transplant waiting time for deceased-donor kidney recipients with allograft failure within 1 year of transplant may benefit the kidney waitlist through decrease in proportion of deceased-donor kidneys discarded.